aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.08−0.91 (-18.24%)
Close on Nov 18, 2026Market cap $400.20MP/E –Yield –
aTYR PHARMA profit margin
Profit margin (net margin) is net income as a percentage of revenue.
aTYR PHARMA's profit margin for the twelve months ending Dec 31, 2025 was -39009.5%. For fiscal 2025 it was -39009.5%, against -27243.8% the year before. The highest annual figure on record is -155.2% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -39009.5% | −11765.6 |
| FY2024 | Dec 31, 2024 | -27243.8% | −12969.3 |
| FY2023 | Dec 31, 2023 | -14274.5% | −13838.0 |
| FY2022 | Dec 31, 2022 | -436.5% | −281.4 |
| FY2020 | Dec 31, 2020 | -155.2% | +3689.4 |
| FY2019 | Dec 31, 2019 | -3844.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -13549.5% | −13309.2 |
| Q1 FY2024 | Mar 31, 2024 | -6591.9% | −2133.1 |
| Q3 FY2023 | Sep 30, 2023 | -3212.5% | +198.1 |
| Q4 FY2022 | Dec 31, 2022 | -72.4% | −94.2 |
| Q4 FY2020 | Dec 31, 2020 | -240.2% | +3907.7 |
| Q3 FY2020 | Sep 30, 2020 | -4458.8% | −1390.8 |
| Q2 FY2020 | Jun 30, 2020 | -3410.6% | +2810.7 |
| Q1 FY2020 | Mar 31, 2020 | 21.7% | – |
| Q4 FY2019 | Dec 31, 2019 | -4147.9% | – |
| Q3 FY2019 | Sep 30, 2019 | -3067.9% | – |
| Q2 FY2019 | Jun 30, 2019 | -6221.3% | – |
See a number that looks wrong?